1. Discovery of novel cosmeceuticals (cosmetic products that have medicinal or
drug-like benefits) and nutraceuticals (dietary supplement or food ingredient)
by innovative anti-aging methods for healthy aging in skincare and nutrition

2. THE NEXT INGREDIENT IN ANTI-AGING SKIN CARE
Chemical peels
Exfoliants
CoQ10
Niacinamide
Peptides (EGF)
Retinol
Sunscreen
ingredients
Botox
Hyaluronic acid
Probiotics
Microalgal
Resveratrol
Stem cells
Anti-aging
Skincare
Compositions
ingredients
“cosmeceutical” refers to cosmetic products
that have medicinal or drug-like benefits

3. GENETIKSIGNAL ANTI-AGING INNOVATION
DIETARY/
CALORIC
RESTRICTION
mTORC1
MITOCHONDRIA
Free radicals
ANTIOXIDANTS
Aging
Enzymes (collagen, elastin)
mRNA TRANSLATION
AUTOPHAGY

4. Aging can be slowed: Dietary restriction
0
0.2
0.4
0.6
0.8
1
0 20 40 60 80
Age (Cell Divisions)
FractionViable
10 20 30 40
Age (days)
0
0.2
0.4
0.6
0.8
1
0
FractionViable
Control
DR
Control
DR
DR
DR
Control
Control
DR in yeast accomplished by decreasing glucose concentration from
2% to 0.5% or lower

5. VALUE PROPOSITION
Exclusive
license for IP;
methods U. S.
patents
Chemo
Preventative
Non-
carcinogen
No FDA
approval for
cosmeceutical
Low cost of
starting
compounds
modulaTOR
discovery portfolio
Naturally
derived next gen
antioxidants

6. MARKET OPPORTUNITY
Cosmeceuticals, Nutraceuticals
* Technology Insight Report – Antiaging skin care compositions –Patent InSight Pro (2010)
Cosmeceuticals –US industry study with forecasts for 2015 & 2020 by Freedonia Group, July 2011
Anti-aging
• Global market for anti-aging products (which
includes pharmaceutical products for age related
health issues, supplements and appearance based
products which include skin care) is an estimated
$291.9 billion by the year 2015 *
-100
0
100
200
300
400
$millions
Vitamin A
Vitamin E
Vitamin C
CoQ10
$700 million cosmeceutical skin care antioxidant market by 2017

7. BUSINESS MODEL
Distributed partnering model
(Kauffman foundation)
Product
Definition
Company
Discovery
Definition
Development
Delivery
IN-LICENSING
OUT-LICENSING

8. BUSINESS STRATEGY
YEAR 1
• COMPOUND
IDENTIFICATION
• IN VITRO ANTI-
AGING YEAST
SCREENS
YEAR 2
• MAMMALIAN/
SKIN
FIBROBLAST
IN VITRO
SCREENS
• CRO
• MARKETING
YEAR 3
• PRODUCTION
• MANUFACTURING
• FORMULATION
AND DELIVERY
VALUE INFLECTION
“COSMECEUTICAL DISCOVERY”
SERIES A ROUND
VALUE CREATION
REVENUE
(CUSTOMER)
ROI IS 5-10X
Strategic Alliances/ Partners:
Cosmetics companies (Cosmeceuticals)
Pharma consumer health companies (Nutraceuticals)

9. MANAGEMENT TALENT:
CSO/CEO: GINA DEVASAHAYAM, BIOENTREPRENEUR
VP-CHEMISTRY: RYAN VAN DE WATER, MEDICINAL CHEMIST
SCIENTIFIC ADVISORY BOARD: MATT KAEBERLEIN,
ASSOCIATE PROFESSOR
FRANCIS BURROWS,
CSO, AARDEN PHARMA
LEGAL COUNSEL: CHARLES KATZ,
EMERGING COMPANY & VC PRACTICE,
MORRISON & FOERSTER
BUSINESS ADVICE AND CONSULTING: INNOVATE PROGRAM
(JHU, UMBC, MARYLAND)
PROPRIETARY INTELLECTUAL ASSET:
IP FROM UNIVERSITY OF WASHINGTON, SEATTLE

10. THANK YOU!
www.genetiksignal.com